Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory cell culture study
PubMed 9771884 · doi:10.1016/s0014-5793(98)01085-0
What was done
In vitro laboratory assays evaluated the effects of delta9-tetrahydrocannabinol (THC) and N-acetylsphingosine (a cell-permeable ceramide analog) on C6.9 glioma cells, other transformed neural cell lines, and primary astrocytes and neurons. Apoptosis was assessed via DNA fragmentation and loss of plasma membrane asymmetry. Sphingomyelin hydrolysis was measured, and the involvement of the CB1 cannabinoid receptor was tested using the antagonist SR141716.
What was found
The abstract reports no numerical values, concentrations, or statistical metrics. THC stimulated sphingomyelin hydrolysis and induced apoptosis in C6.9 glioma cells. THC and N-acetylsphingosine induced apoptosis in several transformed neural cell lines but spared primary astrocytes and neurons. The CB1 antagonist SR141716 failed to block either THC-induced apoptosis or sphingomyelin breakdown in C6.9 cells.
Why it matters
The study outlines a potential mechanism for cannabinoid-mediated anti-tumor activity in neural cancers, showing selective toxicity to transformed cells via a CB1-independent sphingomyelin pathway.
Limits
This is an in vitro bench study without in vivo or clinical human data. The abstract provides no quantitative effect sizes, concentrations, sample sizes, or assay replicates. The findings cannot be directly applied to human glioblastoma treatment.
Cited by
- supports Dr. Cristina Sánchez at the University of Madrid demonstrated in a laboratory setting that THC kills cancer cells.